Neonatal Encephalopathy Clinical Trial
Official title:
Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia: A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate Safety and Efficacy (Phase II Study)
Around the time of birth, some babies experience a condition called asphyxia, which means that their brain and other organs do not receive enough blood and/or oxygen to work properly. This life-threatening condition accounts for nearly 1 out of 4 deaths of all babies around the world, and often leads to severe brain damage, cerebral palsy, epilepsy, and trouble with learning and functioning in everyday life. At this time, no treatment is available to repair the brain damage caused by asphyxia. Excitingly, a drug called sildenafil (Viagra®) is already given safely to babies who suffer from increased blood pressure in their lungs' vessels. Recent studies using a laboratory model of asphyxia at birth suggest that sildenafil may also repair the brain damage caused by asphyxia. Similarly, recent small studies have shown that it is both feasible and safe to give sildenafil to human babies, who suffered from asphyxia at birth. These studies also highlight the first promising signs that sildenafil may improve how the brains of these babies work, which is consistent with the abovementioned laboratory studies. On the basis of these previous researches, the investigators predict that sildenafil can repair the damage to a baby's brain. The investigators will test whether sildenafil can be safely given to a large group of human babies who suffer from asphyxia at birth, and will confirm whether sildenafil improves or not how their brains and hearts/lungs work. This project will enable to determine whether sildenafil is a promising treatment for repairing brain damage in babies who suffer from asphyxia at birth. This project may also provide new solutions for these babies to improve their future life.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | June 2028 |
Est. primary completion date | October 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Minutes to 48 Hours |
Eligibility | Inclusion Criteria: - Male and female neonates meeting the criteria for induced hypothermia: - Gestational age =36weeks and birth weight =1800g; - Evidence of fetal distress, i.e., history of an acute perinatal event, cord pH =7.0 or base deficit - 16 mEq/L; - Evidence of neonatal distress, such as an Apgar score =5 at 10 minutes, postnatal blood gas pH obtained within the first hour of life = 7.0 or base deficit = - 16 mEq/L, or a continued need for ventilation initiated at birth and continued for at least 10 minutes; - Evidence of moderate to severe neonatal encephalopathy by an abnormal neurological exam and/or an amplitude-integrated electroencephalogram (aEEG). They will receive whole-body cooling to an esophageal temperature of 33.5°C, initiated within the first 6 hours of life, continued for 72 hours, and then they will be slowly rewarmed using standard protocol. - Evidence of brain injury on a brain magnetic resonance imaging (MRI) performed on day 2 of life. Exclusion Criteria: - Neonates with complex congenital heart disease - Neonates with cerebral malformations - Neonates with genetic syndrome - Neonates with intraventricular and/or intraparenchymal hemorrhage on MRI performed on day 2 of life - Moribund infants not expected to survive |
Country | Name | City | State |
---|---|---|---|
Canada | Montreal Children's Hospital | Montréal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Pia Wintermark |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Ejection fraction (EF) in % (reflecting left ventricular function) and tricuspid annular plane systolic excursion (TAPSE) in cm (reflecting right ventricular function) | Secondary outcome to explore efficacy (cardiopulmonary hemodynamics) | Day 2 to 4 of life | |
Primary | Extent of brain injury | Primary outcome to explore efficacy (brain injury) | Day 30 of life, compared to day 2 of life | |
Secondary | Serious adverse events | Close monitoring for adverse events such as death, hypotension, persistent pulmonary hypertension, altered renal or hepatic function, etc to assess the safety of sildenafil | Day 1 to 10 of life |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05471336 -
Enteral Feeding and Splanchnic NIRS Values in Infants With Neonatal Encephalopathy (NE)
|
N/A | |
Recruiting |
NCT05514340 -
Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
|
Phase 2 | |
Recruiting |
NCT04603547 -
Transcutaneous Carbon Dioxide Monitoring in Neonates Receiving Therapeutic Hypothermia for Neonatal Encephalopathy
|
||
Completed |
NCT01913340 -
Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)
|
Phase 1/Phase 2 | |
Completed |
NCT00581581 -
CoolCap Followup Study-Coordination of Participating Centers
|
N/A | |
Recruiting |
NCT05772416 -
Neonatal Neurological Examination to Detect Infants at Risk
|
||
Completed |
NCT03122808 -
Uterine Activity in Moderate-Severe Neonatal Encephalopathy: A Case Control Study
|
||
Recruiting |
NCT02544100 -
Neonatal Neurologic Intensive Care Network of China
|
||
Completed |
NCT03380013 -
OMT to Improve Feeding After Hypothermia
|
N/A | |
Active, not recruiting |
NCT03409770 -
Optimising the Duration of Cooling in Mild Encephalopathy
|
N/A | |
Recruiting |
NCT05127070 -
Evaluating the NeoTree in Malawi and Zimbabwe
|
||
Not yet recruiting |
NCT05756296 -
The Long-term Consequences of Neonatal Encephalopathy in the Hypothermia Era
|
||
Recruiting |
NCT04432662 -
Darbepoetin in Neonatal Encephalopathy Trial
|
Phase 2 | |
Recruiting |
NCT02793999 -
Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia
|
||
Not yet recruiting |
NCT05889507 -
Cooling in Mild Encephalopathy
|
N/A | |
Recruiting |
NCT05848271 -
Natural History Study of Patients With HPDL Mutations
|
||
Not yet recruiting |
NCT04176471 -
TIME Study: Therapeutic Hypothermia for Infants With Mild Encephalopathy
|
N/A | |
Completed |
NCT01309711 -
Magnetic Resonance Biomarkers in Neonatal Encephalopathy
|
||
Recruiting |
NCT04225975 -
Neonate Cerebral Activity in Immediate Post Partum
|
N/A | |
Recruiting |
NCT05610085 -
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
|
Phase 2 |